Related Experiment Video
Updated: Sep 25, 2025

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
The Association of Plasma Amyloid-β and Cognitive Decline in Cognitively Unimpaired Population
Jin Wang1, Ling Gao1, Jie Liu1
1Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.
Purpose:
This study investigates the relationship between baseline plasma Aβ and cognitive decline during follow-up in cognitively unimpaired population.
Materials And Methods:
Cognitively unimpaired population was selected from people who lived in the suburbs of Xi'an, China. The levels of plasma Aβ1-42 and Aβ1-40 were tested using commercial enzyme-linked immunosorbent assay (ELISA). The mini-mental state examination (MMSE) and neuropsychological battery were used to assess cognition. Two years later, MMSE was tested again, and significant cognitive decline was defined as a decrease in MMSE scores ≥5 points. Logistic regression analysis was performed to analyze the relationship between baseline plasma Aβ and cognitive change during the two-year follow-up.
Results:
A total of 1144 participants completed the study, among whom 59 subjects (5.2%) presented significant cognitive decline. The high plasma Aβ1-42 level group had more significant cognitive decline (P = 0.023). Multivariable logistic regression analysis showed that significant cognitive decline was associated with the high levels of baseline plasma Aβ1-42 (OR = 1.043, 95% CI: 1.005-1.083, P = 0.026). However, significant cognitive decline was not associated with baseline plasma Aβ1-40 levels and Aβ1-42 /Aβ1-40 ratio.
Conclusion:
Population with high level of baseline plasma Aβ1-42 manifested significant cognitive decline over 2 years; however, further investigation on the dynamics of plasma Aβ and long-term follow-up are needed.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Cognitive Development During Adulthood
Alzheimer's Disease: Treatment
Dementia
The progression of dementia is generally gradual....
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

